Zheng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zheng Wang has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Renjun Pei
Suzhou Institute of Nano-tech and Nano-bionics, Chinese Academy of Sciences
7 shared publications Xiaochun Xie
School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China
4 shared publicationsBingyuan Fei
Department of Gastrointestinal Colorectal Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China
3 shared publicationsHui Fang
School of Medicine, South China University of Technology, Guangzhou, Guangdong, 510006, China
3 shared publicationsJine Wang
CAS Key Laboratory of Nano-Bio Interface Suzhou Institute of Nano-Tech and Nano-Bionics Chinese Academy of Sciences, Suzhou, China
3 shared publicationsJunjie Li
Institute for Materials Chemistry and Engineering, Kyushu University, 744 Motooka, Nishi-ku, Fukuoka, 819-0395, Japan
3 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Elsevier in Materials Today Bio
- Vol. 40
Mitochondrial remodeling by extracellular vesicles co-delivering functional mitochondria and a mitophagy inducer for neuropathic pain relief
- 1 September 2026
- Published by Elsevier in Materials Today Bio
- Vol. 40
Open AccessMitochondrial remodeling by extracellular vesicles co-delivering functional mitochondria and a mitophagy inducer for neuropathic pain relief
- 15 August 2026
- Published by Elsevier in Biomaterials
- Vol. 337, 124557
A sonogenetic antigen-presenting nanoplatform enables spatiotemporal control of calcium signalling in T cells for enhanced cancer immunotherapy
- 15 August 2026
- Published by Elsevier in Biomaterials
- Vol. 337, 124557
A sonogenetic antigen-presenting nanoplatform enables spatiotemporal control of calcium signalling in T cells for enhanced cancer immunotherapy
- 21 October 2025
- Published by Elsevier in Biomaterials
- Vol. 327, 123796
Co-delivery of CO/H2 gases for synergistic radiosensitization and intestinal protection in peritoneal metastases therapy
- 21 October 2025
- Published by Elsevier in Biomaterials
- Vol. 327, 123796
Co-delivery of CO/H2 gases for synergistic radiosensitization and intestinal protection in peritoneal metastases therapy
- Open Access
- 18 June 2025
- Published by Elsevier in Materials Today Bio
- Vol. 33, 101996
Reprogramming cellular senescence of hepatic stellate cells to combat liver fibrosis by targeted nanodrugs
- 18 June 2025
- Published by Elsevier in Materials Today Bio
- Vol. 33, 101996
Open AccessReprogramming cellular senescence of hepatic stellate cells to combat liver fibrosis by targeted nanodrugs
- 4 December 2024
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (4) , 1159-1179
Progress in Chinese medicine monomers and their nanoformulations on myocardial ischemia/reperfusion injury
The aim of this review is to elucidate the pathomechanism of MIRI and present the latest developments in the use of TCM monomers and nanomaterials in combination with TCM monomers for the treatment of MIRI.
- 4 December 2024
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13 (4) , 1159-1179
Progress in Chinese medicine monomers and their nanoformulations on myocardial ischemia/reperfusion injury
The aim of this review is to elucidate the pathomechanism of MIRI and present the latest developments in the use of TCM monomers and nanomaterials in combination with TCM monomers for the treatment of MIRI.
- Open Access
- 1 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (44) , eadp7022
Reprogramming cellular senescence in the tumor microenvironment augments cancer immunotherapy through multifunctional nanocrystals
Harnessing the immunogenic potential of senescent tumor cells provides an opportunity to remodel tumor microenvironment (TME) and boost antitumor immunity. However, this potential needs to be sophisticatedly wielded to avoid additional immunosuppressive capacity of senescent cells. Our study shows that blocking the JAK2/STAT3 pathway enhances immunogenic efficacy of Aurora kinase inhibitor alisertib (Ali)–induced senescence by reducing immunosuppressive senescence-associated secretory phenotype (SASP) while preserving immunogenic SASP. Hypothesizing that SASP reprogramming with Ali and JAK2 inhibitor ruxolitinib (Rux) will benefit cancer immunotherapy, we create nanoparticulate crystals (Ali-Rux) composed of Ali and Rux with a fully active pharmaceutical ingredient. Immunization with Ali-Rux–orchestrated senescent cells promotes stronger activation of antigen-presenting cells, enhancing antitumor immune surveillance. This approach remodels the TME by increasing CD8 + T cell and NK recruitment and activation while decreasing MDSCs. Combined with PD-L1 blockade, Ali-Rux elicits a durable antitumor immune response, suggesting the TME reshaping approach as a potential cancer immunotherapy.
- 1 November 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (44) , eadp7022
Open AccessReprogramming cellular senescence in the tumor microenvironment augments cancer immunotherapy through multifunctional nanocrystals
Harnessing the immunogenic potential of senescent tumor cells provides an opportunity to remodel tumor microenvironment (TME) and boost antitumor immunity. However, this potential needs to be sophisticatedly wielded to avoid additional immunosuppressive capacity of senescent cells. Our study shows that blocking the JAK2/STAT3 pathway enhances immunogenic efficacy of Aurora kinase inhibitor alisertib (Ali)–induced senescence by reducing immunosuppressive senescence-associated secretory phenotype (SASP) while preserving immunogenic SASP. Hypothesizing that SASP reprogramming with Ali and JAK2 inhibitor ruxolitinib (Rux) will benefit cancer immunotherapy, we create nanoparticulate crystals (Ali-Rux) composed of Ali and Rux with a fully active pharmaceutical ingredient. Immunization with Ali-Rux–orchestrated senescent cells promotes stronger activation of antigen-presenting cells, enhancing antitumor immune surveillance. This approach remodels the TME by increasing CD8 + T cell and NK recruitment and activation while decreasing MDSCs. Combined with PD-L1 blockade, Ali-Rux elicits a durable antitumor immune response, suggesting the TME reshaping approach as a potential cancer immunotherapy.
- Open Access
- 28 September 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-15
Leveraging adrenergic receptor blockade for enhanced nonalcoholic fatty liver disease treatment via a biomimetic nanoplatform
Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive lipid accumulation, steatosis and fibrosis. Sympathetic nerves play a critical role in maintaining hepatic lipid homeostasis and regulating fibrotic progression through adrenergic receptors expressed by hepatocytes and hepatic stellate cells; however, the use of sympathetic nerve-focused strategies for the treatment of NAFLD is still in the infancy. Herein, a biomimetic nanoplatform with ROS-responsive and ROS-scavenging properties was developed for the codelivery of retinoic acid (RA) and the adrenoceptor antagonist labetalol (LA). The nanoplatform exhibited improved accumulation and sufficient drug release in the fibrotic liver, thereby achieving precise codelivery of drugs. Integration of adrenergic blockade effectively interrupted the vicious cycle of sympathetic nerves with hepatic stellate cells (HSCs) and hepatocytes, which not only combined with RA to restore HSCs to a quiescent state but also helped to reduce hepatic lipid accumulation. We demonstrated the excellent ability of the biomimetic nanoplatform to ameliorate liver inflammation, fibrosis and steatosis. Our work highlights the tremendous potential of a sympathetic nerve-focused strategy for the management of NAFLD and provides a promising nanoplatform for the treatment of NAFLD. The potential of adrenoceptor-blockade strategy was explored for reprogromming the activated hepatic stellate cells and reducing hepatic lipid accumulation in the treatment of NAFLD. A biomimetic nanoplatform with ROS-responsive and ROS-scavenging properties was tailored for achieving precise delivery of retinoic acid and adrenoceptor antagonists as well as consuming ROS to provide anti-inflammatory benefits. The biomimetic nanoplatform integrating adrenoceptor blockade exhibits excellent ability to reduce liver steatosis and alleviate inflammation and fibrosis, thereby achieving enhanced NAFLD treatment.
- 28 September 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-15
Open AccessLeveraging adrenergic receptor blockade for enhanced nonalcoholic fatty liver disease treatment via a biomimetic nanoplatform
Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive lipid accumulation, steatosis and fibrosis. Sympathetic nerves play a critical role in maintaining hepatic lipid homeostasis and regulating fibrotic progression through adrenergic receptors expressed by hepatocytes and hepatic stellate cells; however, the use of sympathetic nerve-focused strategies for the treatment of NAFLD is still in the infancy. Herein, a biomimetic nanoplatform with ROS-responsive and ROS-scavenging properties was developed for the codelivery of retinoic acid (RA) and the adrenoceptor antagonist labetalol (LA). The nanoplatform exhibited improved accumulation and sufficient drug release in the fibrotic liver, thereby achieving precise codelivery of drugs. Integration of adrenergic blockade effectively interrupted the vicious cycle of sympathetic nerves with hepatic stellate cells (HSCs) and hepatocytes, which not only combined with RA to restore HSCs to a quiescent state but also helped to reduce hepatic lipid accumulation. We demonstrated the excellent ability of the biomimetic nanoplatform to ameliorate liver inflammation, fibrosis and steatosis. Our work highlights the tremendous potential of a sympathetic nerve-focused strategy for the management of NAFLD and provides a promising nanoplatform for the treatment of NAFLD. The potential of adrenoceptor-blockade strategy was explored for reprogromming the activated hepatic stellate cells and reducing hepatic lipid accumulation in the treatment of NAFLD. A biomimetic nanoplatform with ROS-responsive and ROS-scavenging properties was tailored for achieving precise delivery of retinoic acid and adrenoceptor antagonists as well as consuming ROS to provide anti-inflammatory benefits. The biomimetic nanoplatform integrating adrenoceptor blockade exhibits excellent ability to reduce liver steatosis and alleviate inflammation and fibrosis, thereby achieving enhanced NAFLD treatment.
- Open Access
- 12 June 2024
- Published by Wiley in Advanced Science
- Vol. 11 (30) , e2400630
Leveraging Senescent Cancer Cell Membrane to Potentiate Cancer Immunotherapy Through Biomimetic Nanovaccine
Senescent cancer cells are endowed with high immunogenic potential that has been leveraged to elicit antitumor immunity and potentially complement anticancer therapies. However, the efficacy of live senescent cancer cell‐based vaccination is limited by interference from immunosuppressive senescence‐associated secretory phenotype and pro‐tumorigenic capacity of senescent cells. Here, a senescent cancer cell‐based nanovaccine with strong immunogenicity and favorable potential for immunotherapy is reported. The biomimetic nanovaccine integrating a senescent cancer cell membrane‐coated nanoadjuvant outperforms living senescent cancer cells in enhancing dendritic cells (DCs) internalization, improving lymph node targeting, and enhancing immune responses. In contrast to nanovaccines generated from immunogenic cell death‐induced tumor cells, senescent nanovaccines facilitate DC maturation, eliciting superior antitumor protection and improving therapeutic outcomes in melanoma‐challenged mice with fewer side effects when combined with αPD‐1. The study suggests a versatile biomanufacturing approach to maximize immunogenic potential and minimize adverse effects of senescent cancer cell‐based vaccination and advances the design of biomimetic nanovaccines for cancer immunotherapy.
- 12 June 2024
- Published by Wiley in Advanced Science
- Vol. 11 (30) , e2400630
Open AccessLeveraging Senescent Cancer Cell Membrane to Potentiate Cancer Immunotherapy Through Biomimetic Nanovaccine
Senescent cancer cells are endowed with high immunogenic potential that has been leveraged to elicit antitumor immunity and potentially complement anticancer therapies. However, the efficacy of live senescent cancer cell‐based vaccination is limited by interference from immunosuppressive senescence‐associated secretory phenotype and pro‐tumorigenic capacity of senescent cells. Here, a senescent cancer cell‐based nanovaccine with strong immunogenicity and favorable potential for immunotherapy is reported. The biomimetic nanovaccine integrating a senescent cancer cell membrane‐coated nanoadjuvant outperforms living senescent cancer cells in enhancing dendritic cells (DCs) internalization, improving lymph node targeting, and enhancing immune responses. In contrast to nanovaccines generated from immunogenic cell death‐induced tumor cells, senescent nanovaccines facilitate DC maturation, eliciting superior antitumor protection and improving therapeutic outcomes in melanoma‐challenged mice with fewer side effects when combined with αPD‐1. The study suggests a versatile biomanufacturing approach to maximize immunogenic potential and minimize adverse effects of senescent cancer cell‐based vaccination and advances the design of biomimetic nanovaccines for cancer immunotherapy.
- 3 May 2024
- Published by Elsevier in Biomaterials
- Vol. 309, 122603
Regulating tumor innervation by nanodrugs potentiates cancer immunochemotherapy and relieve chemotherapy-induced neuropathic pain
- 3 May 2024
- Published by Elsevier in Biomaterials
- Vol. 309, 122603
Regulating tumor innervation by nanodrugs potentiates cancer immunochemotherapy and relieve chemotherapy-induced neuropathic pain
- Open Access
- 5 April 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-14
Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy
The combination of immune checkpoint inhibitors and immunogenic cell death (ICD) inducers has become a promising strategy for the treatment of various cancers. However, its efficacy remains unmet because of the dense stroma and defective vasculatures in the tumor microenvironment (TME) that restricts the intratumoral infiltration of cytotoxic T lymphocytes (CTLs). Herein, cancer-associated fibroblasts (CAFs)-targeted nanoemulsions are tailored to combine the ICD induction and the TME reprogramming to sensitize checkpoint blockade immunotherapy. Melittin, as an ICD inducer and an antifibrotic agent, is efficiently encapsulated into the nanoemulsion accompanied by a nitric oxide donor to improve its bioavailability and tumor targeting. The nanoemulsions exhibited dual functionality by directly inducing direct cancer cell death and enhancing the tumoral immunogenicity, while also synergistically reprogramming the TME through reversing the activated CAFs, decreasing collagen deposition and restoring tumor vessels. Consequently, these nanemulsions successfully facilitated the CTLs infiltration and suppressing the recruitment of immunosuppressive cells. A combination of AE-MGNPs and anti-CTLA-4 antibody greatly elicited a striking level of antitumor T-cell response to suppress tumor growth in CAFs-rich colorectal tumor models. Our work emphasized the integration of the ICD induction with simultaneous modulation of the TME to enhance the sensitivity of patients to checkpoint blockade immunotherapy.
- 5 April 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-14
Open AccessTumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy
The combination of immune checkpoint inhibitors and immunogenic cell death (ICD) inducers has become a promising strategy for the treatment of various cancers. However, its efficacy remains unmet because of the dense stroma and defective vasculatures in the tumor microenvironment (TME) that restricts the intratumoral infiltration of cytotoxic T lymphocytes (CTLs). Herein, cancer-associated fibroblasts (CAFs)-targeted nanoemulsions are tailored to combine the ICD induction and the TME reprogramming to sensitize checkpoint blockade immunotherapy. Melittin, as an ICD inducer and an antifibrotic agent, is efficiently encapsulated into the nanoemulsion accompanied by a nitric oxide donor to improve its bioavailability and tumor targeting. The nanoemulsions exhibited dual functionality by directly inducing direct cancer cell death and enhancing the tumoral immunogenicity, while also synergistically reprogramming the TME through reversing the activated CAFs, decreasing collagen deposition and restoring tumor vessels. Consequently, these nanemulsions successfully facilitated the CTLs infiltration and suppressing the recruitment of immunosuppressive cells. A combination of AE-MGNPs and anti-CTLA-4 antibody greatly elicited a striking level of antitumor T-cell response to suppress tumor growth in CAFs-rich colorectal tumor models. Our work emphasized the integration of the ICD induction with simultaneous modulation of the TME to enhance the sensitivity of patients to checkpoint blockade immunotherapy.